Skip to main content
MorphoSys gains option for Vivoryon's QPCTL inhibitors program

MorphoSys has obtained an exclusive option for international rights to develop and market Vivoryon Therapeutics's family of QPCTL inhibitors. The small molecule glutaminyl-peptide cyclotransferase-like inhibitors will be used to develop cancer therapies in combination with MorphoSys' own candidate tafasitamab, or MOR208, to treat relapsed/refractory diffuse large B-cell lymphomas.

Full Story: